Open access · US-GOV via ClinicalTrials.gov Clinical trial

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Authors not listed

Mayo Clinic · 2025

Cellular senescence Human Randomized controlled trial

Abstract

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-27 MST

Cite this

APA

Anonymous. (2025). Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women. <em>Mayo Clinic</em>. https://clinicaltrials.gov/study/NCT07057310

Vancouver

Anonymous. Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women. Mayo Clinic. 2025.

BibTeX

@misc{anon2025AgingW, title = {Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women}, author = {Anonymous}, journal = {Mayo Clinic}, year = {2025}, }